Three new antiepileptic drugs (AEDs) are finding increasing use in medical practice. To examine their efficacy and side-effect profile, 483 patients with epilepsy attending either a specialized epilepsy clinic or general neurology clinic under the care of a single consultant neurologist were reviewed. Of these patients 127 had received lamotrigine, 100 vigabatrin and 27 gabapentin. In all but three patients the indication had been epilepsy refractory to other treatments.
INTRODUCTION
Epilepsy is a common condition with a prevalence of around 0.5% of the population ~. It has a particularly high psychosocial morbidity 2 and is a significant cause of premature and sudden death 3.
Accordingly the ultimate goal in patients with epilepsy is to render them seizure free without inducing adverse events. In the majority of cases this can be achieved using a single well established agent such as sodium valproate, carbamazepine or phenytoin. However, in a significant minority of patients, particularly those with complex partial seizures and secondarily generalized partial seizures, mono-or polytherapy with such agents proves unsuccessful. In these circumstances the new AEDs, vigabatrin, lamotrigine and gabapentin are increasingly used as adjunctive therapy. These agents have been licensed for use since 1989, 1991 and 1993, respectively. Vigabatrin works by inhibiting the enzyme GABA transaminase and thereby raises the levels of GABA, an inhibitory neurotransmitter. Lamotrigine acts by blocking voltage-dependent sodium channels thereby stabilizing neuronal membranes and reducing the release of excitatory neurotransmitters such as glutamate and aspartate. Whilst gabapentin is a structural analogue of GABA, it does not affect its neuronal content or uptake, or bind to its receptors and its mechanism of antiepileptic action remains undefined. The main purpose of this audit was to examine the efficacy and tolerability of these new AEDs in clinical practice. Secondary aims were to assess the extent of their use and to build up a profile of the patients in whom they are employed.
METHODS
Four hundred and eighty-three patients attending either a specialized epilepsy clinic or general neurology clinic between September 1994 and February 1995 were assessed. All of the patients were under the care of a single consultant neurologist (JIM) and were attending one of several centres throughout Northern Ireland at the Royal Victoria, Belfast City, Antrim, MidUlster, Waveney, Moyle and Carrick Hospitals.
The current and previous drug therapy was reviewed when those patients exposed to any of the three new AEDs were identified and the duration of epilepsy and the seizure frequency before and during treatment was established. All patients were categorized appropriately as to seizure type.
A drug was deemed to be efficacious if it rendered a pateint seizure free for at least six months or produced a >50% reduction in seizure frequency. All significant adverse events reported by patients were recorded irrespective of whether it resulted in drug discontinuation.
RESULTS"
One hundred and seventy-two (35.6%) of the patients surveyed had received at least one of lamotrigine, vigabatrin or gabapentin at some stage. There were 94 females and 78 males with an age range of 26-63 years (mean, 35 years). One hundred and twenty-seven patients had received lamotrigine, 100 vigabatrin and 27 gabapentin. Apart from three patients commenced on lamotrigine as part of a first-line monotherapy trial, the indication had been epilepsy refractory to other treatments.
The duration of epilepsy ranged from onset (3 cases) to 50 years (average, 20.3 years). Seizure frequency ranged from zero (3 cases) to 224/month with an average frequency of 18.3/month and a median frequency of 4 month.
As can be seen from Table 1 , the vast majority of patients had partial seizures with or without secondary generalization. These types of seizures are usually more difficult to control than primary generalized seizures (which occurred in only a small portion of the group. Of those patients commenced on lamotrigine, 71 (56%) were continuing on the drug at the time of the audit. Corresponding figures for vigabatrin and gabapentin were 45 (45%) and 13 (48.1%), respectively. In most cases the new AEDs formed part of a polytherapy r6gime but in nine patients on lamotrigine, five on vigabatrin and one on gabapentin they represented monotherapy.
Excluding the three patients in the monotherapy trial from onset of epilepsy, lamotrigine produced a >50% reduction in seizure frequency in 40 patients and rendered a further five seizure free giving a total efficacy of 36.3%. Vigabatrin produced a >50% reduction in 24 patients and rendered five patients seizure free (29% efficacy), whilst gabapentin enabled one patient to become seizure free and another three to have a >50% reduction in seizure frequency (15% efficacy). In addition to this definite benefit regarding seizure frequency a small and similar proportion of patients (3-4%) reported a decrease in seizure severity without a decrease in seizure frequency with each of the drugs.
Of the 11 patients (6.5%) rendered seizure free none had been exposed to more than one of the new AEDs. Nine of these patients had complex partial seizures only, one had a combination of both simple partial and complex partial seizures and one had primary generalized epilepsy. This select group of patients had a higher average (29 vs. 18.3/month) and median (14 vs. 4/month) seizure frequency than for the group as a whole but had a shorter average duration of epilepsy (11.1 vs. 20.3 years).
Because of the apparent discrepancy between the efficacies of lamotrigine and vigabatrin and that of gabapentin, the profile of patients receiving gabapentin was examined more closely. Twenty-five of 27 patients (92.6%) had already received lamotrigine and/or vigabatrin prior to commencing gabapentin, 16 (59.3%) having received both. The average duration of epilepsy of the group was 23.3 years whilst the average and median seizure frequencies were 19.3/month and 6/month, respectively.
Significant adverse events were many and various and some patients experienced more than one ( Table 2 ). The specific behavioural/ psychological adverse events described with lamotrigine were depression (five patients), aggressive behaviour (four patients), obsessional behaviour (two patients), confusion (two patients), anxiety (two patients) and reduced concentration span (one patient). The skin rash occurring with lamotrigine became apparent <2 weeks after commencement of the drug in all but one patient and five of the six patients were having concomitant treatment with sodium valproate. All of those patients describing diplopia on lamotrigine were already established on carbamazepine and each of those experiencing weight gain, hair loss and postural tremor were previously on sodium valproate.
Tolerance of effect was noted in 12 patients on vigabatrin, two having been seizure free and 10 having had a >50% reduction in seizure frequency. This phenomenon was also noted in two patients having had a >50% reduction in seizures on gabapentin and one previously having similar benefit with lamotrigine.
Overall, adverse events resulted in drug withdrawal in 28.3% on lamotrigine, 23% on vigabatrin and 18.5% on gabapentin. Lack of efficacy preceded drug withdrawal in 15% on lamotrigine, 27% on vigabatrin and 33.3% on gabapentin. In addition 5% of patients on vigabatrin were withdrawn due to drug tolerance and one patient (0.8%) discontinued lamotrigine due to pregnancy.
DISCUSSION
Epilepsy is a common condition in the community confronting neurologists, physicians and general practitioners alike. Indeed the average general practice might expect to have 10 patients with epilepsy, three of whom may be refractory to treatment. After a long period during which the treatment options for this latter group of patients had remained static, recent years have seen the development of several new agents. This has been most welcome and will hopefully continue. However, apart from creating opportunities these developments give rise to important questions about efficacy, tolerability, interactions and appropriate indications particularly in view of the cost of the new AEDs compared to the well established drugs.
In our study the extent of exposure to at least one of the new AEDs was high (35.6%). In the light of previous experience it is unsurprising that they were generally used in patients having partial seizures (92.4%). Superficially at least, it might be said that the results on efficacy are disappointing given that the primary goal is to render patients seizure free and this was achieved in only 6.5% of cases. However this was a group of patients with a long history of resistant, frequent and predominantly partial seizures in whom approximately one-third derived significant benefit from both lamotrigine and vigabatrin. The lower efficacy found with gabapentin, whilst in line with the results of others 4, may represent a slightly unfair reflection on the drug given that in over 90% of patients at least one of the other two new drugs had already been tried. As it is the most recently available of the new AEDs by some two years it may tend to be used in the most resistant of cases and in our practice it does seem to have often been used as a treatment of last resort. Also recent experience in the USA would suggest that an optimal dosage of gabapentin may be 2.4 g/day 5 which is rather higher than the dosage received by the earlier patients in our group.
Tolerability of the three agents varied although the range of common adverse events was broadly similar. Gabapentin which, like vigabatrin, is not metabolized in the liver and is excreted unchanged in the urine was the best tolerated whilst 28.3% on lamotrigine which undergoes hepatic metabolism withdrew due to adverse events.
Behavioural/psychological side effects have been well described with vigabatrin 6 but this audit has found them occurring with all three drugs and leading to drug discontinuation in >70% of those affected. Predictably increased seizure frequency when it occurs almost invariably leads to drug discontinuation (87.5% of cases) and overall is the second commonest cause of drug withdrawal. Although frequently overcome, drowsiness was found to be a significant problem with vigabatrin and gabapentin.
The occurrence of skin rash with lamotrigine was broadly in line with expectations at around 5% 7 . The finding that all but one of these patients was concurrently on sodium valproate, a hepatic enzyme inhibitor, emphasizes the need to commence lamotrigine at a lower dosage and more slowly in such circumstances.
Diplopia is a well known toxic effect of carbamazepine as are tremor, hair loss and weight gain with sodium valproate. However in a significant number of patients in this study these effects did not materialize until after starting lamotrigine. As lamotrigine had no effect on the pharmacokinetics of either drug this suggests a pharmacodynamic interaction. This is further suggested as in our experience these effects disappeared with a reduction in dosage of carbamazepine or sodium valproate. Many of these and other effects of lamotrigine can be prevented by starting with a small initial dose, building up gradually and reducing the dosage of concomitant AEDs as side effects appear.
Drug tolerance is a deterioration occurring after an initially favourable outcome which fails to improve despite subsequent alteration in dosage. It has been previously described with vigabatrin 8 and occurred in 12% of our patients on vigabatrin but was not a problem with lamotrigine. It may also prove to be a significant feature with gabapentin although larger numbers and a longer period of follow-up are required to assess this than were available in our study.
This study reflects the wider choice of drugs available to treat refractory epilepsy. Naturally none of the three new AEDs addresses all or even most of the problems faced but they do represent a significant addition to patient management. As they remain relatively 'young' drugs, further evaluation of their long-term efficacy and tolerability is required whilst the search for improved broad spectrum successors with no interactions and few side-effects continues.
